RUSSIA RESPONDS TO WESTERN SANCTIONS WITH PATENT RETALIATION -
On March 6, 2022, the Russian government retaliated against the West’s imposition of sanctions by issuing a decree permitting patented innovations to be used...more
6/27/2022
/ Appeals ,
Biotechnology ,
Cosmetics ,
Dietary Supplements ,
EU ,
France ,
Intellectual Property Protection ,
Medical Devices ,
Patent Litigation ,
Patent Validity ,
Patents ,
Pharmaceutical Industry ,
Russia ,
Sanctions ,
Trademark Litigation ,
Trademarks
Today’s global healthcare marketplace is marked by unprecedented transformation. This presents both challenges and opportunity to today’s market participants. We know how important it is to structure cross-border investments...more
6/1/2022
/ Anti-Kickback Statute ,
Artificial Intelligence ,
Cross-Border ,
Global Market ,
Healthcare ,
Investment ,
Investors ,
Life Sciences ,
Medical Technology Companies ,
Merger Controls ,
Pharmaceutical Industry ,
Technology Sector ,
Telemedicine
Sovereign Wealth Fund Investment in the Global Healthcare Industry -
Sovereign Wealth Funds (SWF) seek out investments that are resilient, conducive to their aims and objectives, and reasonably free from market...more
5/5/2021
/ Appeals ,
Bonds ,
Collaboration ,
Copyright Ownership ,
Coronavirus/COVID-19 ,
Court of Justice of the European Union (CJEU) ,
Data Privacy ,
Drug Pricing ,
Employees ,
Employer Liability Issues ,
Employer Mandates ,
Enforcement Actions ,
EU ,
European Commission ,
European Data Protection Board (EDPB) ,
Germany ,
Healthcare Workers ,
Intellectual Property Protection ,
International Data Transfers ,
Investment Funds ,
Investors ,
Patents ,
Pharmaceutical Industry ,
Private Equity Funds ,
Sovereign Wealth Funds ,
Vaccinations
Life sciences organizations have become some of the world’s most watched businesses and the industry as a whole is facing heightened scrutiny in light of the COVID-19 pandemic.
The transactional and regulatory issues as...more
Companies frequently encounter challenges in the manufacture and supply of their innovative products, in particular with respect to process development and production capacity.
In our latest webinar, we review how key...more
3/17/2021
/ Biotechnology ,
Capacity ,
Intellectual Property Protection ,
Liability ,
Life Sciences ,
Manufacturers ,
Pharmaceutical Industry ,
Regulatory Requirements ,
Supply Agreements ,
Warranties ,
Webinars
Key Take-Away: To avoid ambiguity, parties drafting manufacture and supply agreements should explicitly set out the factors that they deem relevant in assessing a party’s efforts. The manufacturing party may wish to...more